Market revenue in 2023 | USD 385.0 million |
Market revenue in 2030 | USD 735.9 million |
Growth rate | 9.7% (CAGR from 2023 to 2030) |
Largest segment | Diagnostics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 76.05% in 2023. Horizon Databook has segmented the Japan nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The market in Japan is expected to witness a significant growth during the forecast period owing to increasing number of initiatives undertaken by government organizations. For instance, the Japan Radioisotope Association (JRIA) intends to promote effective use of radioisotopes and provide better quality of life. According to investigations by JRIA, the demand for higher quality scans is increasing.
On the other hand, for SPECT, the number is about a million annually. Mo-99 in Japan is imported from other countries; hence, the supply is limited in the country. Therefore, in June 2018, JRIA formed the Japan Foundation of Medical Isotope Development (JAFMID) to promote the domestic production of technetium acid.
For instance, in December 2019, Fuzionaire Radioisotope Technologies K.K. (Fuzionaire Dx) and Department of Nuclear Medicine and Tracer Kinetics at Osaka University entered into a collaborative research agreement to drive the discovery of novel radiotherapeutic agents for the treatment of cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into Japan nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account